查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1901619

卵巢癌藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、腫瘤類型、配銷通路、地區和競爭格局分類，2021-2031年預測

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Tumor Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球卵巢癌藥物市場規模預計將從2025年的43.2億美元成長至2031年的63.6億美元，複合年成長率（CAGR）為6.66%。卵巢癌藥物涵蓋多種藥理干預措施，包括鉑類化療藥物、聚（ADP-核糖）聚合酶（PARP）抑制劑和血管生成抑制劑，旨在治療卵巢、輸卵管和腹膜的惡性腫瘤。該市場的主要驅動力是全球卵巢癌發生率的上升以及老年人口的成長，因為年齡是該疾病的重要風險因素。

市場概覽
預測期 2027-2031
市場規模：2025年 43.2億美元
市場規模：2031年 63.6億美元
複合年成長率：2026-2031年 6.66%
成長最快的細分市場 烷基化劑
最大的市場 北美洲

主要市場促進因素

PARP抑制劑和標靶療法的進步正在從根本上改變卵巢癌的臨床治療，它們具有更精準的作用機制，與傳統化療相比能夠顯著改善患者的預後。市場正經歷著向抗體藥物偶聯物和維持療法的重大轉變，這些藥物和療法針對特定的生物標記物，例如葉酸受體α。

主要市場挑戰

新型標靶療法和免疫療法的高昂費用嚴重阻礙了全球卵巢癌藥物市場的成長。這些先進療法的高定價結構造成了巨大的經濟負擔，迫使醫療保險機構實施嚴格的報銷政策，而這些政策往往將患者資格限制在一小部分人群中。

主要市場趨勢

針對鉑類抗藥性疾病的新療法研發正日益關注不同的組織學亞型，而非將抗藥性病例視為一個整體進行治療。低度漿液性卵巢癌（LGSOC）標靶抑制劑的出現便是這一趨勢的例證。 LGSOC是一種罕見且對化療抗藥性的疾病，其致病機制與RAS/MAPK路徑密切相關。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球卵巢癌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依腫瘤類型（上皮性卵巢癌、卵巢低度惡性潛能腫瘤、生殖細胞腫瘤、性索間質腫瘤）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美卵巢癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲卵巢癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區卵巢癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲卵巢癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲卵巢癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球卵巢癌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • AstraZeneca, Plc
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • CH Boehringer Sohn Ko. KG
  • Novartis AG

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 12865

The Global Ovarian Cancer Drugs Market will grow from USD 4.32 Billion in 2025 to USD 6.36 Billion by 2031 at a 6.66% CAGR. Ovarian cancer drugs encompass a diverse range of pharmacological interventions, including platinum-based chemotherapies, poly (ADP-ribose) polymerase (PARP) inhibitors, and angiogenesis inhibitors, designed to treat malignancies of the ovaries, fallopian tubes, and peritoneum. The market is primarily driven by the increasing global incidence of ovarian cancer and the growing geriatric population, as age constitutes a significant risk factor for the disease.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.32 Billion
Market Size 2031USD 6.36 Billion
CAGR 2026-20316.66%
Fastest Growing SegmentAlkylating Agents
Largest MarketNorth America

Key Market Drivers

Advancements in PARP inhibitors and targeted therapeutics are fundamentally altering the clinical management of ovarian cancer by offering precise mechanisms of action that improve patient outcomes compared to traditional chemotherapy. The market is witnessing a significant shift towards antibody drug conjugates and maintenance therapies that target specific biomarkers like folate receptor alpha. This transition is exemplified by the commercial success of recently approved agents which are rapidly capturing market share.

Key Market Challenges

The prohibitive cost associated with novel targeted therapies and immunotherapies constitutes a substantial impediment to the growth of the global ovarian cancer drugs market. High pricing structures for these advanced regimens lead to significant financial toxicity, forcing healthcare payers to implement stringent reimbursement policies that often restrict patient eligibility to a narrow subset of the population. In many regions, particularly developing economies, the resulting high out-of-pocket expenses effectively place these life-extending treatments out of reach for many individuals.

Key Market Trends

The development of novel therapies for platinum-resistant disease is increasingly focusing on distinct histological subtypes rather than treating resistant cases as a monolithic group. This trend is exemplified by the emergence of targeted inhibitors for low-grade serous ovarian cancer (LGSOC), a rare and chemo-resistant form of the disease driven by the RAS/MAPK pathway. Unlike broad-spectrum chemotherapy or antibody-drug conjugates, these regimens utilize RAF/MEK clamps to disrupt oncogenic signaling in tumors harboring KRAS mutations.

Key Market Players

  • AstraZeneca, Plc
  • GlaxoSmithKline, Plc
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Novartis AG

Report Scope:

In this report, the Global Ovarian Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Tumor Type:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumor
  • Germ Cell Tumor
  • Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ovarian Cancer Drugs Market.

Available Customizations:

Global Ovarian Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ovarian Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ovarian Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tumor Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ovarian Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tumor Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Ovarian Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tumor Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Ovarian Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tumor Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Ovarian Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tumor Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ovarian Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tumor Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Ovarian Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tumor Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tumor Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Ovarian Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tumor Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Ovarian Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tumor Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Ovarian Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tumor Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ovarian Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tumor Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Ovarian Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tumor Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Ovarian Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tumor Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Ovarian Cancer Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Tumor Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Ovarian Cancer Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Tumor Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Ovarian Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tumor Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ovarian Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tumor Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Ovarian Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tumor Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Ovarian Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tumor Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Ovarian Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tumor Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ovarian Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tumor Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Ovarian Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tumor Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Ovarian Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tumor Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ovarian Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca, Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline, Plc
  • 15.3. Merck & Co.
  • 15.4. Clovis Oncology, Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Bristol-Myers Squibb Co.
  • 15.7. Eli Lilly and Company
  • 15.8. Amgen Inc.
  • 15.9. C.H. Boehringer Sohn Ko. KG
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer